<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
      <PMID Version="1">35588245</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>19</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1365-2125</ISSN>
          <JournalIssue CitedMedium="Internet">
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
              <Day>19</Day>
            </PubDate>
          </JournalIssue>
          <Title>British journal of clinical pharmacology</Title>
          <ISOAbbreviation>Br J Clin Pharmacol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>The role of placebo response in the efficacy outcome assessment in viloxazine extended-release pivotal trials in pediatric subjects with ADHD.</ArticleTitle>
        <ELocationID EIdType="doi" ValidYN="Y">10.1111/bcp.15412</ELocationID>
        <Abstract>
          <AbstractText Label="AIMS" NlmCategory="OBJECTIVE">Four Phase 3 studies evaluated efficacy and safety of viloxazine extended-release in the treatment of ADHD. The primary efficacy objective - change from baseline in ADHD Rating Scale-5 (ADHD-RS-5) Total score at end of study (EOS) - was not met in one of the studies (812P304). A band-pass analysis was performed to evaluate the impact of placebo response on the results.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">The distribution of placebo response at EOS of each trial was evaluated. The 2.5<sup>th</sup> and 97.5<sup>th</sup> percentiles of the distribution of ADHD-RS-5 Total score were used as boundaries for the band-pass analysis. An independent mixed model for repeated measures analysis was conducted for each trial using all eligible data (active and placebo) from the total, and band-pass filtered populations.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">The 2.5<sup>th</sup> and 97.5<sup>th</sup> percentiles at EOS were 3.5 and 53.5, respectively. Application of the band-pass filter (filtering out all subjects [active, n=305 (32.1%) and placebo, n=134 (33.5%)] of clinical sites with placebo scores &lt;3.5 or &gt;53.5) revealed statistically significant improvement at the primary endpoint (600-mg/day viloxazine ER vs. placebo) in Study 812P304 (mean [CI]=4.9537 [0.5405-9.3669]), previously masked by a high placebo response (mean [CI]=3.5756 [-0.3332-7.4844]). The outcome of the analysis indicated that the impact of the band-pass adjustment is greater when placebo response is higher.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This analysis indicated that a higher placebo response in Study 812P304 confounded the assessment of treatment effect. Application of the band-pass methodology confirmed the positive results of the three prior studies and the signal detection confounder in the fourth study.</AbstractText>
          <CopyrightInformation>This article is protected by copyright. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Nasser</LastName>
            <ForeName>Azmi</ForeName>
            <Initials>A</Initials>
            <Identifier Source="ORCID">0000-0003-0514-8410</Identifier>
            <AffiliationInfo>
              <Affiliation>Supernus Pharmaceuticals, Inc.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gomeni</LastName>
            <ForeName>Roberto</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Pharmacometrica, Lieu-dit Longcol, La Fouillade, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Zhao</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Supernus Pharmaceuticals, Inc.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hull</LastName>
            <ForeName>Joseph T</ForeName>
            <Initials>JT</Initials>
            <AffiliationInfo>
              <Affiliation>Supernus Pharmaceuticals, Inc.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Busse</LastName>
            <ForeName>Gregory D</ForeName>
            <Initials>GD</Initials>
            <AffiliationInfo>
              <Affiliation>Formerly with Supernus Pharmaceuticals, Inc.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Melyan</LastName>
            <ForeName>Zare</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Formerly with Supernus Pharmaceuticals, Inc.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fava</LastName>
            <ForeName>Maurizio</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Psychiatry, Massachusetts General Hospital, MA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>O'Neal</LastName>
            <ForeName>Welton</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Supernus Pharmaceuticals, Inc.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rubin</LastName>
            <ForeName>Jonathan</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Supernus Pharmaceuticals, Inc.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>05</Month>
          <Day>19</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Br J Clin Pharmacol</MedlineTA>
        <NlmUniqueID>7503323</NlmUniqueID>
        <ISSNLinking>0306-5251</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">ADHD</Keyword>
        <Keyword MajorTopicYN="N">ADHD-RS-5</Keyword>
        <Keyword MajorTopicYN="N">attention-deficit/hyperactivity disorder</Keyword>
        <Keyword MajorTopicYN="N">band-pass analysis</Keyword>
        <Keyword MajorTopicYN="N">placebo response</Keyword>
        <Keyword MajorTopicYN="N">treatment effect</Keyword>
        <Keyword MajorTopicYN="N">viloxazine extended-release</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>22</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>22</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>19</Day>
          <Hour>16</Hour>
          <Minute>45</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>aheadofprint</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35588245</ArticleId>
        <ArticleId IdType="doi">10.1111/bcp.15412</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
